arrow
P

Paola Zagami

European Institute of Oncology IRCCS
H指数:18
被引数:1,884

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title

口服选择性雌激素受体降解剂(SERDs)用于治疗激素受体阳性、HER2阴性乳腺癌

2026-05-011
PRE
Impact of Breast Cancer on Sexuality and Psycho-Physical Wellbeing: Survey Analysis

乳腺癌对性功能和身心健康的影晌:调查分析

2026-03-090
OAAI
Corrigendum to: “Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis” [Eur J Cancer 145 (2021) 197–209]

勘误: “Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis” [Eur J Cancer 145 (2021) 197–209]

2025-11-290
PRE
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment

HER2+转移性乳腺癌接受一线治疗时肿瘤浸润淋巴细胞对预后的影响

2025-05-100
OA
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology

放射性配体疗法在转移性乳腺癌中的应用:利用精准肿瘤学

2025-05-010
OAAI
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

HER2阳性早期乳腺癌(EBC)患者新辅助治疗期间残留病灶(RD)生物学及基因表达变化的预后价值

2024-12-010
PRE
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study

转移性三阴性炎性乳腺癌患者的免疫检查点抑制剂 (integrle): 一项国际队列研究

2024-12-010
PRE
Molecular tumor board in patients with metastatic breast cancer

转移性乳腺癌患者的分子肿瘤板

2024-10-301
PRE
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials

年龄对早期临床试验中研究的新型癌症药物安全性和有效性的影响

2024-08-012
PRE
Immune checkpoint inhibitors for triple-negative inflammatory breast cancer (INCORPORATE): an international multicenter retrospective analysis
2024-05-020
PRE